# Introduction to Bioinformatics and Computational Biology

2021-03-02

## Contents

1	Cou	urse information	11
	1.1	Contributors	11
2	Inti	roduction	13
	2.1	Brief history of bioinformatics	14
	2.2	Should I take this course?	14
	2.3	Course information	14
	2.4	Lab 1	14
3	Hig	h throughput sequencing	15
	3.1	Three generations of sequencing technologies	15
	3.2	FASTQ and FASTQC	15
	3.3	Early sequence alignment (1 with 1) $\dots \dots \dots \dots$	15
	3.4	Sequence search algorihtms (1 with many)	16
	3.5	Borrow-Wheeler Aligner (many with many)	16
	3.6	Alignment output	16
4	RN	A-seq Quantification	17
	4.1	Introduction to RNA-seq experiment	17
	4.2	RNA quality control and experimental design	17
	4.3	Alignment	17
	4.4	RNA-seq QC	17
	4.5	RNA-seq expression index	17
	4 6	RSEM and Salmon	17

4		CONTENTS

	4.7	RNA-seq read distribution	17
	4.8	Lab 2	17
5	Diff	ferential expression, FDR, GO, and GSEA	19
	5.1	DESeq2 library normalization	20
	5.2	DESeq2 variance stabilization	20
	5.3	Multiple hypotheses testing and False Discovery Rate $\ \ \ldots \ \ldots$	20
	5.4	DESeq2 gene filtering	20
	5.5	Gene Ontology (GO analysis)	20
	5.6	Gene Set Enrichent Analysis (GSEA)	20
	5.7	DESeq2 tutorial	20
6	Clu	stering	21
	6.1	Heatmap and clustering quality	21
	6.2	Hierarchical cluster	21
	6.3	K means cluster	21
	6.4	Pick K and consensus clustering	21
	6.5	Batch effect removal	21
	6.6	Lab3	21
7	Din	nension Reduction	23
	7.1	Principal Component Analysis: idea behind PCA	23
	7.2	Principal Component Analysis: PCA applications	23
	7.3	Multidimensional Scaling (MDS)	23
	7.4	Linear discriminant Analysis (LDA)	24
8	Cla	ssification	<b>25</b>
	8.1	Introduction	25
	8.2	Supervised learning	26
	8.3	Cross validation	26
	8.4	Regression	26
	8.5	Regularization	26
	8.6	KNN	26

5

	8.7	Decision trees	26
	8.8	Random forest	26
	8.9	SVM	26
	8.10	Lab 4	26
9	Mod	dule I Review	27
	9.1	Module I review	27
	9.2	Analysis Scenario 1	27
	9.3	Analysis Scenario 2	27
10	Trai	ascription Factor Motif Finding	29
	10.1	Transcription regulation and motif representation	29
	10.2	Motif finding using expectation maximization	29
	10.3	Motif finding using Gibbs sampler $\dots$	29
	10.4	Gibbs sampler intuition and transcription factor motif databases	29
	10.5	Motif finding general practices $\dots \dots \dots \dots \dots$	29
11	Trai	ascription Factor Motif Finding	31
11		nscription Factor Motif Finding  Transcription regulation	<b>31</b> 31
11	11.1	-	
11	11.1 11.2	Transcription regulation	31
11	11.1 11.2 11.3	Transcription regulation	31 31
11	11.1 11.2 11.3 11.4	Transcription regulation	31 31 31
11	11.1 11.2 11.3 11.4 11.5	Transcription regulation	31 31 31 31
11	11.1 11.2 11.3 11.4 11.5 11.6	Transcription regulation	31 31 31 31 31
	11.1 11.2 11.3 11.4 11.5 11.6 11.7	Transcription regulation	31 31 31 31 31 31
	11.1 11.2 11.3 11.4 11.5 11.6 11.7	Transcription regulation	31 31 31 31 31 31 31
	11.1 11.2 11.3 11.4 11.5 11.6 11.7 <b>ChI</b> 12.1	Transcription regulation	31 31 31 31 31 31 31 31
	11.1 11.2 11.3 11.4 11.5 11.6 11.7 <b>ChI</b> 12.1 12.2	Transcription regulation	31 31 31 31 31 31 31 33 33
	11.1 11.2 11.3 11.4 11.5 11.6 11.7 <b>ChI</b> 12.1 12.2 12.3	Transcription regulation  Motif representation  EM  Gibbs sampler  Gibbs intuition  Motif finding in eukaryotes  Known motif database  P-seq, Expression Integration  Motif finding in eukaryotes, and ChIP-seq  MACS and ChIP-seq QC	31 31 31 31 31 31 31 33 33

6 CONTENTS

13 Epigenetics, DNA Methylation	35
13.1 Intro to DNA Methylation	35
13.2 DNA Methylation Pattern and Function	35
13.3 DNA Methylation in Diseases	35
13.4 Techniques to Measure DNA Methylation	35
14 Histone Modifications , Chromatin Accessibility	37
14.1 Nucleosome Positioning	37
14.2 Introduction to Histone Modifications	37
14.3 Infer Transcription Factor Binding from Histone Mark Dynamics	37
14.4 Using Histone Marks to Infer Gene Functions	37
14.5 Introduction to DNase-seq and ATAC-seq $\ \ldots \ \ldots \ \ldots$	37
14.6 Infer TF from Differential Genes Using LISA	37
14.7 DNase-seq	37
14.8 Summary of Epigenetics and Chromatin	37
15 Long Range Chromatin Interactions	39
15.1 Chromatin interactions	39
15.2 HiC	39
15.3 HiC contact map	39
15.4 HiC normalization	39
15.5 Fractal globule	39
15.6 Loops	39
15.7 Domains	39
15.8 Compartments	39
15.9 Phase separation	39
16 Hidden Markov Model	41
16.1 Intro to HMM	41
16.2 Pb1: Forward & backward procedure	41
16.3 Pb2: Viterbi algorithm	41
16.4 Pb3: Parameter estimation	41
16.5 HMM application	41

CONTENTS	7

17	Module II Review	43
	17.1 Module II Review	43
	17.2 Practive Questions	43
18	SNP and GWAS	45
	18.1 SNP and LD	45
	18.2 Family-based vs case-control association studies	45
	18.3 GWAS studies and catalog	45
	18.4 GTEx and eQTL	45
19	GWAS and Epigenomics	47
	19.1 Find tissue / cell type $\ \ldots \ \ldots \ \ldots \ \ldots \ \ldots \ \ldots$	47
	19.2 Identify causal SNPs and genes	47
	19.3 Predict phenotypes	47
20	Single-cell RNA-seq (1)	49
	20.1 Intro to scRNA-seq	49
	20.2 Smart, Droplet, microwell, SCI-based	49
	20.3 QC	49
	20.4 Normalization	49
	20.5 Imputation	49
	20.6 Dimension reduction	49
	20.7 Clustering	49
	20.8 t-SNE and UMAP	49
21	Single-cell RNA-seq (2)	<b>51</b>
	21.1 Annotate scRNA-seq clusters	51
	21.2 Differential expression	51
	21.3 Batch effect removal	51
	21.4 Pseudotime	51
	21.5 Overload 10X	51
	21.6 Other applications (CITE-seq, multi-seq, spatial transcriptomics)	51

8 CONTENTS

<b>22</b>	scATAC-seq	<b>53</b>
	22.1 Intro to scATAC-seq	53
	22.2 Sample and cell QC $\dots$	53
	22.3 Dimension reduction, clustering & visualization	53
	22.4 Differential peaks and annotations	53
	22.5 Integration with scRNA-seq	53
23	Module III Review	<b>55</b>
	23.1 Module III Review	55
<b>24</b>	Cancer Genome Sequencing, Mutation analyses	<b>57</b>
	24.1 Intro to TCGA	57
	24.2 Cancer mutation characterization	57
	24.3 Cancer mutation patterns	57
	24.4 Tumor purity and clonality	57
	24.5 Interpret tumor mutations	57
	24.6 Find cancer genes	57
	24.7 Summary and future	57
<b>25</b>	Cancer Subtyping, Survival Analyses	<b>59</b>
	25.1 TCGA expression	59
	25.2 Tumor subtypes	59
	25.3 Survival analysis	59
	25.4 GoF Oncogenes and LoF TS $\ \ldots \ \ldots \ \ldots \ \ldots \ \ldots$	59
	25.5 Chromatin regulator mutations in cancer	59
	25.6 DNA methylation and CIMP	59
26	Targeted Therapy, Drug Resistance, Compound and Genetic Screens	61
	26.1 Hallmarks of cancer	62
	26.2 Chemo vs targeted therapy	62
	26.3 Drug resistance	62
	26.4 Synthetic lethality	62

9

	26.5	Precision medicine	62
	26.6	Tumor (bulk vs scRNA-seq), mice, cell lines	62
	26.7	Compound screens	62
	26.8	Genetic screens	62
	26.9	Tumor heterogeneity	62
27	Can	cer Immunotherapy (1)	63
		Systemic immunotherapy	63
		Personalized immunotherapy	63
		HLA and neoantigens	63
		Tumor immune deconvolution	63
		T cell signaling (PD1/PDL1, etc)	63
		Other immune-cells (scRNA-seq)	63
	21.0	Other minimune-cens (screwa-seq)	00
<b>2</b> 8	Can	cer Immunotherapy (2)	65
	28.1	TCR analysis	65
	28.2	BCR analysis	65
	28.3	$\label{eq:Microbiome} \mbox{Microbiome} \ \dots $	65
	28.4	Immunotherapy response biomarkers	65
	28.5	Targeted the rapy as immune-modulators	65
	28.6	Epigenetic therapy as immune-modulators	65
29	CRI	SPR Screens	67
		CRISPR and KO	67
		CRISPRa and CRISPRi	67
		CRISPR design and outcome	67
		CRISPR screens & DepMap	67
		CRISPR screen analysis	67
		CRISPR screens in drug response	67
		CRISPR screens in immunology	67
		Enhancer CRISPR screen	67
		CRISPR screens + scRNA-seq	67
		<u>*</u>	

10	CONTENTS

30 Module IV Review and Course Review	69
30.1 Module IV Review	69
30.2 Course Review	69

#### Course information

This is the course material for STAT115/215 BIO/BST282 at Harvard University.

All the YouTube videos in this course are organized under the 2021 STAT115 playlist.

#### 1.1 Contributors

Xiaole Shirley Liu Harvard University and Dana-Farber Cancer Institute Joshua Starmer StatQuest
Martin Hemberg Wellcome Sanger Institute
Ting Wang Washington University
Feng Yue Northwestern University
Gad Getz Harvard University and Broad Institute

Ming Tang Yang Liu Bo Yuan Jack Kang Scarlett Qian Jiazhen Rong Phillip Nicol Maartin De Vries

We thank many colleagues in the community, who helped Dr. Liu in prepare the STAT115/215 BIO/BST282 course over the years. Some of the lecture slides acknowledged their contributions, but these contributors are not individually acknowledged here.

### Introduction

ก 1	Brief history	C	f 1: -	_
<i>.</i>	Bridt higtory	z or mini	ntormatic	
<b>4.</b> L	<b>DITCI IIISUUI V</b>	יטנט נט י		

- 2.1.1 Protein structure wave
- 2.1.2 Gene expression wave
- 2.1.3 Genome sequencing wave
- 2.1.4 Big data challenge from sequencing
- 2.2 Should I take this course?
- 2.2.1 Bioinformatics vs computational biology
- 2.2.2 Is this class for me?

#### 2.3 Course information

- 2.3.1 Logistics
- 2.3.2 X Shirley Liu lab introduction
- 2.4 Lab 1
- 2.4.1 Introduction
- 2.4.2 Introduction to R
- 2.4.3 Introduction to Bash
- 2.4.4 Getting started with Cannon

# High throughput sequencing

# 3.1 Three generations of sequencing technologies

First generation sequencing is Sanger sequencing. It is the technology that was used to obtain the first human genome sequence.

Second generation sequencing is also called next generation sequencing (NGS) and is the start of high throughput sequencing. It is what scientists use most often nowadays, and Illumina is the market leader. Most of the rest of this course will cover data analysis using second generation sequencing.

Third generation sequencing is single-molecule sequencing. There are many new technologies still under active development, although none has reached market penetration.

#### 3.2 FASTQ and FASTQC

NGS generates FASTQ files. FASTQC is an computational approach to evaluate the quality of your NGS data.

#### 3.3 Early sequence alignment (1 with 1)

In the early days (1970s), scientists were not worried about having to align too many sequences. They wanted to find the best alignment between two sequences. Many bioinformatics courses start with learning these, although it is not the main focus of our course. We included two videos in case you are interested.

The Needlemen-Wunsch algorithm is the earliest algorithm to find the alignment between two sequences and score their similarity.

When two sequences are long, and only a portion of them can align well with each other, the Smith-Waterman algorithm can find the best local sequence alignment. It is still considered the best alignment approach, although it is slow.

#### 3.4 Sequence search algorithms (1 with many)

With more and more sequences available in the public in the 1980s, scientists were interested in finding whether their newly sequenced string has been sequenced before in the public database. Therefore, the fast search algorithm BLAST was developed, using one sequence as the query to find similar sequences from a database.

#### 3.5 Borrow-Wheeler Aligner (many with many)

With NGS, scientists need much faster search (aka mapping) algorithms in order to align the millions of sequences to the reference genome. The current best algorithm is called Borrow-Wheeler Aligner or BWA.

In order to understand BWA, we first need to introduce Borrows-Wheeler transformation and LF mapping

The basic idea of Borrows-Wheeler alignment

#### 3.6 Alignment output

NGS raw data is in FASTQ. Alignment gives you SAM (alignment) or BAM (binary version of SAM) files which contain the sequence information in FASTQ and the mapping locations. BED file is the simpliest, although there is information loss.

## RNA-seq Quantification

- 4.1 Introduction to RNA-seq experiment
- 4.2 RNA quality control and experimental design
- 4.3 Alignment
- 4.4 RNA-seq QC
- 4.5 RNA-seq expression index
- 4.6 RSEM and Salmon
- 4.7 RNA-seq read distribution
- 4.8 Lab 2
- 4.8.1 STAR tutorial
- 4.8.2 RSeQC tutorial
- 4.8.3 RSEM/Salmon Tutorial

# Differential expression, FDR, GO, and GSEA

**DESeq2** is a popular and accurate computational algorithm to detect differential gene expression from RNA-seq data. It includes many elegant quantitative considerations, such as:

- Normalize the gene read counts by library size and composition
- Model gene read counts with negative binomial distribution
- Use hierarchical modeling to stabilize the gene variance
- Use Benjamini-Hochberg to calculate control for false discovery rate of calling differentially expressed genes
- Filter lowly expressed genes to reduce the number of hypotheses to be tested

- 5.1 DESeq2 library normalization
- 5.2 DESeq2 variance stabilization
- 5.3 Multiple hypotheses testing and False Discovery Rate
- 5.4 DESeq2 gene filtering
- 5.5 Gene Ontology (GO analysis)
- 5.6 Gene Set Enrichent Analysis (GSEA)
- 5.7 DESeq2 tutorial

## Clustering

- 6.1 Heatmap and clustering quality
- 6.2 Hierarchical cluster
- 6.3 K means cluster
- 6.4 Pick K and consensus clustering
- 6.5 Batch effect removal
- 6.6 Lab3
- 6.6.1 PCA tutorial
- 6.6.2 Clustering tutorial
- 6.6.3 Combat tutorial
- 6.6.4 DESeq2 Tutorial
- 6.6.5 DAVID/GSEA Tutorial

#### **Dimension Reduction**

RNA-seq samples have tens of thousands of genes, although many genes might not vary much between samples and many others have correlated gene expression. Dimension reduction techniques aim to reduce the dimension of representing each sample with tens of thousands of genes to much fewer demensions, e.g. 2 to 100.

# 7.1 Principal Component Analysis: idea behind PCA.

PCA / SVD automatically outputs PC1, PC2, PC3, etc, with earlier PCs capturing the highest level of variability in the original data. Each PC is a linear combination of raw gene expression, and is orthogonal to all other PCs.

# 7.2 Principal Component Analysis: PCA applications.

PCA is a widely used method to project samples with high dimensions (e.g. with gene expression data) onto two dimensions for better visualization. It is an intuitive way to identify sample clusters, and identify batch effect.

#### 7.3 Multidimensional Scaling (MDS)

MDS can use differential ways to calculate pair-wise distance, then use lower dimensions to satisfy the pair-wise distance. PCA is a special case of MDS.

#### 7.4 Linear discriminant Analysis (LDA)

LDA is not only a dimension reduction method, but also a supervised machine learning method.

#### Classification

#### 8.1 Introduction

Imagine you have RNA-seq of a collection of labeled normal lung and lung cancer tissues. Given a new sample of RNA-seq from the lung with unknown diagnosis, will you be able to predict based on the existing labeled samples and the expression data whether the new sample is normal or tumor? This is a sample classification problem, and it could be solved using **unsupervised** and **supervised** learning approaches.

Unsupervised learning is basically clustering or dimension reduction. You can use hierarchical clustering, MDS, or PCA. After clustering and projection the data to lower dimensions, you examine the labels of the known samples (hopefully they cluster into separate groups by the label). Then you can assign label to the unknown sample based on its distance to the known samples.

**Supervised learning** considers the labels with known samples and tries to identify features that can separate the samples by the label. Cross validation is conducted to evaluate the performance of different approaches and avoid over fitting.

StatQuest has done an amazing job with machine learning with a full playlist of well organized videos. While the full playlist is worth a full course, for the purpose of the course, we will just highlight a number of widely used approaches. They include logistic regression (this is considered statistical machine learning), K nearest neighbors, random forest, and support vector machine (these are considered computer science machine learning).

- 8.2 Supervised learning
- 8.3 Cross validation
- 8.4 Regression
- 8.5 Regularization
- 8.5.1 Ridge regression
- 8.5.2 LASSO regression
- 8.5.2.1 LASSO tutorial in R
- 8.6 KNN
- 8.7 Decision trees
- 8.8 Random forest
- 8.9 SVM
- 8.10 Lab 4
- 8.10.1 K-Nearest Neighbors tutorial
- 8.10.2 Regression/Ridge/LASSO Tutorial
- 8.10.3 Logistic Regression Tutorial
- 8.10.4 Support Vector Machine Tutorial
- 8.10.5 Random Forest Tutorial

## Module I Review

- 9.1 Module I review
- 9.2 Analysis Scenario 1
- 9.3 Analysis Scenario 2

# Transcription Factor Motif Finding

- 10.1 Transcription regulation and motif representation
- 10.2 Motif finding using expectation maximization
- 10.3 Motif finding using Gibbs sampler
- 10.4 Gibbs sampler intuition and transcription factor motif databases
- 10.5 Motif finding general practices

# Transcription Factor Motif Finding

- 11.1 Transcription regulation
- 11.2 Motif representation
- 11.3 EM
- 11.4 Gibbs sampler
- 11.5 Gibbs intuition
- 11.6 Motif finding in eukaryotes
- 11.7 Known motif database

# ChIP-seq, Expression Integration

- 12.1 Motif finding in eukaryotes, and ChIP-seq
- 12.2 MACS and ChIP-seq QC
- 12.3 Identify TF interactions from ChIP-seq motifs
- 12.4 TF target genes and expression integration
- 12.5 Lab 5
- 12.5.1 MACS Tutorial
- 12.5.2 ChIP-seq QC Tutorial
- 12.5.3 TF Motif Finding Tutorial
- 12.5.4 TF Collaborator Tutorial

# Epigenetics, DNA Methylation

- 13.1 Intro to DNA Methylation
- 13.2 DNA Methylation Pattern and Function
- 13.3 DNA Methylation in Diseases
- 13.4 Techniques to Measure DNA Methylation

## Histone Modifications, Chromatin Accessibility

- 14.1 Nucleosome Positioning
- 14.2 Introduction to Histone Modifications
- 14.3 Infer Transcription Factor Binding from Histone Mark Dynamics
- 14.4 Using Histone Marks to Infer Gene Functions
- 14.5 Introduction to DNase-seq and ATAC-seq
- 14.6 Infer TF from Differential Genes Using LISA
- 14.7 DNase-seq
- 14.8 Summary of Epigenetics and Chromatin

## Long Range Chromatin Interactions

- 15.1 Chromatin interactions
- 15.2 HiC
- 15.3 HiC contact map
- 15.4 HiC normalization
- 15.5 Fractal globule
- 15.6 Loops
- 15.7 Domains
- 15.8 Compartments
- 15.9 Phase separation

#### Hidden Markov Model

- 16.1 Intro to HMM
- 16.2 Pb1: Forward & backward procedure
- 16.3 Pb2: Viterbi algorithm
- 16.4 Pb3: Parameter estimation
- 16.5 HMM application

## Module II Review

- 17.1 Module II Review
- 17.2 Practive Questions

## SNP and GWAS

- 18.1 SNP and LD
- 18.2 Family-based vs case-control association studies
- 18.3 GWAS studies and catalog
- 18.4 GTEx and eQTL

## **GWAS** and Epigenomics

- 19.1 Find tissue / cell type
- 19.2 Identify causal SNPs and genes
- 19.3 Predict phenotypes

## Single-cell RNA-seq (1)

- 20.1 Intro to scRNA-seq
- 20.2 Smart, Droplet, microwell, SCI-based
- 20.3 QC
- 20.4 Normalization
- 20.5 Imputation
- 20.6 Dimension reduction
- 20.7 Clustering
- 20.8 t-SNE and UMAP

## Single-cell RNA-seq (2)

- 21.1 Annotate scRNA-seq clusters
- 21.2 Differential expression
- 21.3 Batch effect removal
- 21.4 Pseudotime
- 21.5 Overload 10X
- 21.6 Other applications (CITE-seq, multi-seq, spatial transcriptomics)

## scATAC-seq

- 22.1 Intro to scATAC-seq
- 22.2 Sample and cell QC
- 22.3 Dimension reduction, clustering & visualization
- 22.4 Differential peaks and annotations
- 22.5 Integration with scRNA-seq

## Module III Review

#### 23.1 Module III Review

# Cancer Genome Sequencing, Mutation analyses

- 24.1 Intro to TCGA
- 24.2 Cancer mutation characterization
- 24.3 Cancer mutation patterns
- 24.4 Tumor purity and clonality
- 24.5 Interpret tumor mutations
- 24.6 Find cancer genes
- 24.7 Summary and future

## Cancer Subtyping, Survival Analyses

- 25.1 TCGA expression
- 25.2 Tumor subtypes
- 25.3 Survival analysis
- 25.4 GoF Oncogenes and LoF TS
- 25.5 Chromatin regulator mutations in cancer
- 25.6 DNA methylation and CIMP

## Targeted Therapy, Drug Resistance, Compound and Genetic Screens

- 26.1 Hallmarks of cancer
- 26.2 Chemo vs targeted therapy
- 26.3 Drug resistance
- 26.4 Synthetic lethality
- 26.5 Precision medicine
- 26.7 Compound screens
- 26.8 Genetic screens
- 26.9 Tumor heterogeneity

## Cancer Immunotherapy (1)

- 27.1 Systemic immunotherapy
- 27.2 Personalized immunotherapy
- 27.3 HLA and neoantigens
- 27.4 Tumor immune deconvolution
- 27.5 T cell signaling (PD1/PDL1, etc)
- 27.6 Other immune-cells (scRNA-seq)

## Cancer Immunotherapy (2)

- 28.1 TCR analysis
- 28.2 BCR analysis
- 28.3 Microbiome
- 28.4 Immunotherapy response biomarkers
- 28.5 Targeted therapy as immune-modulators
- 28.6 Epigenetic therapy as immune-modulators

#### **CRISPR Screens**

29.1	CRISPR	and	$\mathbf{K}\mathbf{O}$
49.1	CUISEU	anu	NU

- 29.2 CRISPRa and CRISPRi
- 29.3 CRISPR design and outcome
- 29.4 CRISPR screens & DepMap
- 29.5 CRISPR screen analysis
- 29.6 CRISPR screens in drug response
- 29.7 CRISPR screens in immunology
- 29.8 Enhancer CRISPR screen
- 29.9 CRISPR screens + scRNA-seq

## Module IV Review and Course Review

- 30.1 Module IV Review
- 30.2 Course Review